Furthermore, since tau cytopathology does not compromise MAPT expression in PSP, and supported by studies on an RNA and protein level using brain homogenates [29, 65, 66], a profound reduction or complete loss of tau protein expression (proteopenia) as a pathogenic component is less likely, while continuous feeding of cellular tau seeding by physiological tau administered for therapeutic reasons might even accentuate the pathological process. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.